Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,248 across all filing types
Latest filing 2019-08-28 AGM Information
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract of the newspaper advertisement regarding ....
AGM Information Classification · 95% confidence The document is a notice regarding the 34th Annual General Meeting (AGM) of Bliss GVS Pharma Ltd. It includes details about the AGM date, venue, remote e-voting schedule, book closure dates, and instructions for shareholders. It references the Annual Report for the financial year 2018-19 but does not contain the report itself. The document is primarily an announcement of the AGM and related voting procedures, not the full Annual Report or financial statements. The presence of voting details, book closure, and meeting notice aligns with typical AGM Information filings. The document length is about 11,461 characters, which is consistent with a detailed AGM notice but not a full Annual Report. Therefore, the appropriate classification is AGM Information (AGM-R).
2019-08-28 English
In terms of Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached 34th Annual Report of Bliss ....
Annual Report Classification · 100% confidence The document is titled 'Annual Report of Bliss GVS Pharma Limited for the financial year of 2018-19' and references Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the filing of annual reports. The text includes detailed sections typical of an annual report such as Corporate Information, Board of Directors, Auditors, Financial Section with Independent Auditor's Report, Balance Sheet, Profit and Loss Statement, and Management Discussion and Analysis. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document is the official yearly report covering company activity and full financial performance, fitting the definition of an Annual Report (10-K).
2019-08-27 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter from Bliss GVS Pharma Limited to the National Stock Exchange of India Limited, responding to a query about unusual price movement in the company's shares. It clarifies that there is no material information affecting the company's operations that requires disclosure under SEBI Listing Regulations. The letter is dated August 27, 2019, and is a regulatory communication addressing a surveillance inquiry. It does not contain financial statements, audit information, management discussion, or any report data. It is a regulatory filing responding to a regulatory body inquiry, fitting the category of Regulatory Filings (RNS). The document length is short (1918 characters), and it is not an announcement of a report but a direct regulatory communication.
2019-08-27 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is titled as an "Investor Presentation on Company's performance for the quarter ended June 30, 2019" and contains detailed financial data including standalone and consolidated income statements, operational highlights, and historical financials. It is a presentation format focusing on quarterly financial results and business overview. The presence of detailed quarterly financial figures and operational commentary indicates it is a comprehensive quarterly report rather than a brief earnings release or a simple announcement. The document length is substantial (15,000 characters) and contains actual financial data, so it is not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2019-08-21 English
Enclosed herewith investor presentation on Company's performance for the quarter ended June 30, 2019. Kindly take the same on record.
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation on Company's performance for the quarter ended June 30, 2019" and contains detailed financial data including standalone and consolidated income statements, balance sheets, operational highlights, and quarterly financial performance metrics. It includes financial figures such as operational income, EBITDA, net profit, EPS, and margin analysis for Q1-FY20, as well as historical financial data. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a detailed presentation aimed at investors, focusing on quarterly financial results and operational performance. Therefore, this document fits the category of an Investor Presentation (IP) rather than an Earnings Release (ER) which would be shorter and less detailed, or an Interim/Quarterly Report (IR) which would be more formal and comprehensive in financial statements. Hence, the correct classification is Investor Presentation (IP).
2019-08-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is a regulatory filing notifying shareholders about the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF) as required by law. It includes copies of newspaper advertisements published by the company. This is a standard regulatory compliance announcement and does not fit into more specific categories like financial reports or dividend payment announcements (which would be for active distributions).
2019-08-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.